<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817191</url>
  </required_header>
  <id_info>
    <org_study_id>2016-005</org_study_id>
    <nct_id>NCT02817191</nct_id>
  </id_info>
  <brief_title>Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL</brief_title>
  <official_title>Effects of Holy-Comod and Tears Naturale Forte on Ocular Surface and Tear Inflammatory Mediators in Patients After Phaco+IOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study it to compare the effects of Holy-Comod and Tears Naturale Forte on
      ocular surface and tear inflammatory mediators in patients after Phaco+IOL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>scale of Schirmer I test</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>scale of corneal fluorescein staining</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>scale of noninvasive tear breakup time</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>questionnaire of ocular surface disease index</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>scale of central corneal sensitivity</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>scale of tear meniscus height</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of Interleukin-1α</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of tumor necrosis factor-α</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of nerve growth factor</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of interferon-γ</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of transforming growth factor-β1</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of matrix metalloproteinase-9</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Inflammatory Mediators and Ocular Surface Changes</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Age-related Cataract</condition>
  <arm_group>
    <arm_group_label>Hylo-Comod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients used Hylo-Comod eye drop after phaco+IOL in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tears Naturale Forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylo-Comod eye drop</intervention_name>
    <description>The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL</description>
    <arm_group_label>Hylo-Comod</arm_group_label>
    <other_name>0.3% tobramycin/dexamethasone (TobraDex, Alcon)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tears Naturale Forte eye drop</intervention_name>
    <description>The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL</description>
    <arm_group_label>Tears Naturale Forte</arm_group_label>
    <other_name>0.3% tobramycin/dexamethasone (TobraDex, Alcon)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60-72 years old

          -  classification of lens nucleus is LOCS Ⅱ

        Exclusion Criteria:

          -  patients with previous history of ocular surgery, corneal diseases,uveitis ,ocular
             hypertension or glaucoma ,systemic diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingwu Zhong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHI ZHANG, MD, PhD</last_name>
    <phone>+8613790077756</phone>
    <email>mike0946@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hainan Eye Hospital, Zhongshan Ophthalmic Center of Sun Yat-sen University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingwu Zhong, MD,PhD</last_name>
      <phone>+86(898)68628481</phone>
      <email>zhongxwu@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>November 24, 2016</last_update_submitted>
  <last_update_submitted_qc>November 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xingwu Zhong, MD PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>age-related cataract</keyword>
  <keyword>Holy-Comod</keyword>
  <keyword>Tears Naturale Forte</keyword>
  <keyword>phacoemulsification</keyword>
  <keyword>inflammatory mediators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

